Status:
COMPLETED
Statin Therapy to Improve Medication Adherence
Lead Sponsor:
Duke University
Conditions:
Hypercholesterolemia
HMG COA Reductase Inhibitor Adverse Reaction
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this pilot study is to examine if using genetics can improve statin adherence in patients who should be taking statins but are not because of prior side effects with statins. This study...
Detailed Description
HMG Co-A reductase inhibitors ("statins") are commonly prescribed to lower low density lipoprotein cholesterol (LDLc) and to prevent cardiovascular disease (CVD), a leading cause of morbidity and mort...
Eligibility Criteria
Inclusion
- Current patient (defined as seen in the last year) of the Duke Primary Care at Pickett Road or Center for Living
- Age greater than or equal to 18 years
- Provider interested in prescribing statins for cardiovascular disease prevention
- Ability to provide informed consent
Exclusion
- Prior rhabdomyolysis, defined as CK elevation \> 10 times the upper limit of normal with any statin therapy
- Prior unexplained elevation in hepatic enzymes (AST or ALT \> 3 times upper limit of normal) with any statin therapy
- Use of medications known to interfere with statin metabolism or disposition
- Participation in a drug research study in the past 30 days
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT01894217
Start Date
May 1 2011
End Date
April 1 2014
Last Update
January 8 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Duke Center for Living
Durham, North Carolina, United States, 27705
2
Duke Primary Care Clinic at Pickett Road
Durham, North Carolina, United States, 27705